Roche Plays Down Reliance On TIGIT And Alzheimer’s Drugs For Growth

Company Boasts 51 Late-Stage Candidates

 
• By Andrew McConaghie
Roche_Basel
Roche is banking on its sector-leading R&D expenditure to pay off over the next 5-10 years. • Source: Shutterstock

More from Business

More from Scrip